Extravasation of macromolecules

Advanced Drug Delivery Reviews

Volumn 34, Issue 1, 1998, Pages 93-108

  Takakura, Yoshinobu ^a   Mahato, Ram I ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Extravasation; Macromolecules; Oligonucleotides; Pharmacokinetics; Plasmid DNA; Proteins

Indexed keywords

CONTROLLED DRUG DELIVERY; DNA; DRUG PRODUCTS; GENES; OLIGOMERS; PHARMACOKINETICS; PROTEINS;

EXTRAVASATION; OLIGONUCLEOTIDES;

MACROMOLECULES;

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; DAUNORUBICIN; DOXORUBICIN; DRUG; DRUG CARRIER; INTERFERON; MITOMYCIN C; OLIGONUCLEOTIDE; PROTEIN; TUMOR NECROSIS FACTOR;

BLOOD FLOW VELOCITY; CAPILLARY ENDOTHELIUM; CELL JUNCTION; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; EXTRAVASATION; HUMAN; HYDROPHILICITY; KIDNEY PERFUSION; LIPOPHILICITY; LIVER PERFUSION; LYMPH FLOW; MACROMOLECULE; MEMBRANE TRANSPORT; MOLECULAR SIZE; NONHUMAN; PHYSICAL CHEMISTRY; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0032487363     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00006-4     Document Type: Review

References (100)

1. Tomlinson, E., Biological dispersion and the design of site-specific protein therapeutic systems, in: G. Gregoriadis, A.C. Allison, G. Poste (Eds.), Targeting of Drugs 2, Plenum Press, New York, 1990, pp. 1-20.
2. Tomlinson E. Impact of the new biologies on the medical and pharmaceutical sciences. J. Pharm. Pharmacol. 44(suppl.):1992;147-159.
3. Verniory A., Dubois R., Decsodt P., Lambert P.P. Measurement of the permeability of biological membranes. J. Gen. Physiol. 62:1973;489-507.
4. Sezaki H., Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1:1984;1-38.
5. Sezaki H., Takakura Y., Hashida M. Soluble macromolecular carriers for the delivery of antitumor drugs. Adv. Drug Deliv. Rev. 3:1989;247-266.
6. Hashida M., Nishikawa M., Yamashita F., Takakura Y. Targeted delivery of protein drugs by chemical modification. Drug Dev. Ind. Pharm. 20:1994;581-590.
7. Takakura Y., Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18:1995;207-231.
8. Takakura Y., Mahato R.I., Nishikawa M., Hashida M. Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv. Drug Deliv. Rev. 19:1996;377-399.
9. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution. Pharm. Res. 13:1996;820-831.
10. Hashida M., Mahato R.I., Kawabata K., Miyao T., Nishikawa M., Takakura Y. Pharmacokinetics and targeted delivery of proteins and genes. J. Control. Release. 41:1996;91-97.
11. Mahato R.I., Takakura Y., Hashida M. Development of targeted delivery systems for nucleic acid drugs. J. Drug Target. 4:1997;337-357.
12. Tomlinson E. Microsphere delivery systems for drug targeting and controlled release. Int. J. Pharm. Tech. Prod. Mfr. 4:1983;49-57.
13. Tomlinson E. Theory and practice of site-specific drug delivery. Adv. Drug Deliv. Rev. 1:1987;87-198.
14. Simionescu N. Cellular aspects of transcapillary exchange. Physiol. Rev. 63:1983;1536-1579.
15. V. Kumar, G.S. Banker, Target-oriented drug delivery systems, in: G.S. Banker, C.T. Rhodes (Eds.), Modern Pharmaceutics, 3rd Edition, Marcel Dekker, New York, 1996, pp. 611-680.
16. Petrak K., Goddard P. Transport of macromolecules across the capillary walls. Adv. Drug Deliv. Rev. 3:1989;191-214.
17. Joyner W.L., Kern D.F. Microvascular permeability to macromolecules and its dynamics modulation. Adv. Drug Deliv. Rev. 4:1990;319-342.
18. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;135-187.
19. Renkin E.M. Capillary transport of macromolecules: pores and other endothelial pathways. J. Appl. Physiol. 58:1985;315.
20. A. Taylor, D.N. Granger, Exchange of macromolecules across the microcirculation, in: E.M. Renkin, C.C. Michael (Eds.), Handbook of Physiology, Section 2: The Cardiovascular System, American Physiology Society, Bethesda, MD, 1984, pp. 492-494.
21. Pardridge W.M. Brain metabolism: A perspective from the blood-brain barrier. Physiol. Rev. 63:1983;1481-1535.
22. Karnovsky M.J. The ultrastructural basis of transcapillary exchanges. J. Gen. Physiol. 52:1968;641-696.
23. Venkatachalam M.A., Rennke H.G. The structural and molecular basis of glomerular filtration. Circ. Res. 43:1978;337-347.
24. Bohrer M.P., Baylis C., Humes D., Glassock R.J., Robertson C.R., Brenner B.M. Permselectivity of the glomerular capillary wall. Facilitated filtration of circulating polycations. J. Clin. Invest. 61:1978;72-78.
25. Bohrer M.P., Deen W.M., Robertson C.R., Troy J.L., Brenner B.M. Influence of molecular configuration on the passage of macromolecules across the glomerular capillary wall. J. Gen. Physiol. 74:1979;583-593.
26. Arfors K.-E., Rutilli G., Svensjo E. Microvascular transport of macromolecules in normal and inflammatory conditions. Acta Physiol. Scand. Suppl. 463:1979;93-103.
27. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6:1989;193-210.
28. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agents smancs. Cancer Res. 46:1986;6387-6392.
29. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
30. Jain R.K. Barriers to drug delivery in solid tumors. Scientific Am. 270(7):1994;42-49.
31. J. Baker, I.J. Hidalgo, R.T. Borchardt, Intestinal epithelial and vascular endothelial barriers to peptide and protein delivery, in: V.H.L. Lee (Ed.), Protein and Peptide Drug Delivery, Marcel Dekker, New York, 1991, pp. 359-390.
32. Hashida M., Kato A., Takakura Y., Sezaki H. Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat. Drug Metab. Dispos. 12:1984;492-499.
33. Nishikawa M., Ohtsubo Y., Ohno J.et al. Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. Int. J. Pharm. 85:1992;75-85.
34. Takakura Y., Fujita T., Furitsu H., Nishikawa M., Sezaki H., Hashida M. Pharmacokinetics of succinylated proteins and dextran sulfate in mice: implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors. Int. J. Pharm. 105:1994;19-29.
35. Fujita T., Takakura Y., Sezaki H., Hashida M. Control of disposition characteristics of proteins by direct cationization in mice. Pharm. Sci. 1:1995;371-375.
36. Takagi A., Masuda H., Takakura Y., Hashida M. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther. 275:1995;537-543.
37. Kakutani T., Yamaoka Y., Hashida M., Sezaki H. A new method for assessment of drug disposition in muscle: Application of statistical moment theory to local perfusion systems. J. Pharmacokinet. Biopharm. 13:1985;609-631.
38. U.B. Kompella, V.H.L. Lee, Pharmacokinetics of peptides and protein drugs. in: V.H.L. Lee (Ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 391-484.
39. Sato K., Itakura K., Nishida K., Takakura Y., Hashida M., Sezaki H. Disposition of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the perfused rat liver. J. Pharm. Sci. 78:1989;11-16.
40. 111In-labeled lactosaminated bovine serum albumin in rats. Pharm. Res. 8:1991;1253-1257.
41. Nishida K., Tonegwa C., Nakane S., Takakura Y., Hashida M., Sezaki H. Effect of electric charge on the hepatic uptake of macromolecules in the rat liver. Int. J. Pharm. 65:1990;7-17.
42. Nishida K., Mihara K., Takino T.et al. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 8:1991;437-444.
43. Takakura Y., Mahato R.I., Yoshida M., Kanamaru T., Hashida M. Uptake characteristics of oligonucleotides in the single-pass rat liver perfusion system. Antisense Nucleic Acid Drug Develop. 6:1996;179-183.
44. Yoshida K., Mahato R.I., Kawabata K., Takakura Y., Hashida M. Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharm. Res. 13:1996;597-601.
45. Maack T. Renal clearance and isolated kidney perfusion techniques. Kidney Int. 30:1986;142-151.
46. Mihara K., Mori M., Hojo T., Takakura Y., Sezaki H., Hashida M. Disposition characteristics of model macromolecules in the perfused rat kidney. Biol. Pharm. Bull. 16:1993;158-162.
47. K. Mihara, T. Hojo, M. Fujikawa, Y. Takakura, H. Sezaki, M. Hashida, Disposition characteristics of protein drugs in the perfused rat kidney, 10 (1993) 823-827.
48. Mihara K., Sawai K., Takakura Y., Hashida M. Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification. Biol. Pharm. Bull. 17:1994;296-301.
49. Takakura Y., Mihara K., Hashida M. Control of the disposition profiles of proteins in the kidney via chemical modification. J. Control. Release. 28:1994;111-119.
50. Brenner B.M., Hostetter T.H., Humes H.D. Glomerular permselectivity: barrier function based on distribution of molecular size and charge. Am. J. Physiol. 234:1978;F455-F460.
51. Sawai K., Mahato R.I., Oka Y., Takakura Y., Hashida M. Disposition of oligonucleotides in the isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J. Pharmacol. Exp. Ther. 279:1996;284-290.
52. Venkatachalam M.A., Karnovsky M. Extravascular protein in the kidney: An ultrastructural study of its relation to renal peritubular capillary permeability using protein tracers. Lab. Invest. 27:1972;435-444.
53. Sawai K., Miyao T., Takakura Y., Hashida M. Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res. Dev. 5:1995;279-287.
54. Ohkouchi K., Imoto H., Takakura Y., Hashida M., Sezaki H. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res. 50:1990;1640-1644.
55. Imoto H., Sakamura Y., Ohkouchi K.et al. Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation. Cancer Res. 52:1992;4396-4401.
56. R.K. Jain, L.T. Baxter, Extravasation and interstitial transport in tumors, in: K.L. Audus, T.J. Raub (Eds.), Biological Barriers to Protein Delivery, Plenum Press, New York, 1993, pp. 441-465.
57. A.B. Malik, A. Siflinger-Birnboin, Vascular endothelial barrier function and its regulation, in: K.L. Audus, T.J. Raub (Eds.), Biological Barriers to Protein Delivery, Plenum Press, New York, 1993, pp. 231-267.
58. Audus K.L., Bartel R.L., Hidalgo I.J., Borchardt R.T. The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res. 7:1990;435-451.
59. Takakura Y., Audus K.L., Borchardt R.T. Blood-brain barrier: Transport studies in isolated brain capillaries and in cultured brain endothelial cells. Adv. Pharmacol. 22:1991;137-167.
60. Takakura Y., Audus K.L., Borchardt R.T. Cultured brain microvessel endothelial cells as in vitro models of the blood-brain barrier. NIDA Res. Monogr. Ser. 120:1992;138-151.
61. Raub T.J., Kuentzel S.L., Sawada G.A. Permeability of bovine brain microvessel endothelial cells in vitro: Barrier tightening by a factor released from astroglioma cells. Exp. Cell Res. 199:1992;330-340.
62. Dehouck M.-P., Meresse S., Delorme P., Fruchart J.-C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Nephrochem. 54:1990;1798-1801.
63. Trammel A.M., Borchardt R.T. The effects of astrocytes and glioma cells on the permeability of cultured brain microvessel endothelial cells. Pharm. Res. 6:1989;S88.
64. Rubin L.L., Hall D.E., Porter S.et al. A cell culture model of the blood-brain barrier. J. Cell Biol. 115:1991;1725-1735.
65. Siflinger-Birnboin A., Del Vecchino P.J., Cooper J.A., Blumenstock F.A., Shepard J.M., Malik A.B. Molecular sieving characteristics of the cultured endothelial monolayer. J. Cell. Physiol. 132:1987;111-117.
66. Sahagun G., Moore S.A., Hart M.N. Permeability of neutral vs. anionic dextrans in cultured brain microvascular endothelium. Am. J. Physiol. 259:1990;H162-H166.
67. Hart M.N., Vandyk L.F., Moore S.A., Shasby D., Cancilla P.A. Differentiated opening of the brain endothelial barrier following neutralization of the endothelial luminal anionic charge in vitro. J. Neuropathol. Exp. Neurol. 46:1987;141-153.
68. Descamps L., Dehouck M.-P., Torpier G., Cecchelli R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol. 270:1996;H1149-H1158.
69. Takakura Y., Kato A., Hashida M.et al. Urinary excretion characteristics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate. J. Pharmacobio-Dyn. 8:1985;357-364.
70. Takakura Y., Kitajima M., Matsumoto S., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities. Int. J. Pharm. 37:1987;135-143.
71. Takakura Y., Atsumi R., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular injection. Int. J. Pharm. 37:1987;145-154.
72. Takakura Y., Takagi A., Hashida M., Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4:1987;293-300.
73. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7:1990;339-346.
74. Noguchi A., Takahashi T., Yamaguchi T.et al. Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Jpn. J. Cancer Res. 82:1990;219-226.
75. Duncan R., Koepeckova P., Strohalm J., Hume I.C., Lloyed J.b., Kopeck J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br. J. Cancer. 57:1988;147.
76. Duncan R., Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27:1994;290-306.
77. Yokoyama M., Okano T., Sakurai Y., Ekimoto H., Sibazaki C., Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 50:1991;1640-1644.
78. Katre N.V. The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential. Adv. Drug. Deliv. Rev. 10:1993;91-114.
79. Kitamura K., Takahashi T., Takashima K.et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem. Biophys. Res. Commun. 171:1990;1387-1394.
80. H. Sezaki, Y. Takakura, M. Hashida, Chemical modification and disposition of proteins and peptides: biopharmaceutical aspects, in: D.J.A. Crommelin, K.K. Midha (Eds.), Topics in Pharmaceutical Sciences. Medpharm, Stuttgart, 1991, pp. 47-57.
81. Fujita T., Nishikawa M., Tamaki C., Takakura Y., Hashida M., Sezaki H. Targeted delivery of human superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J. Pharmacol. Exp. Ther. 263:1992;971-978.
82. Nishikawa M., Hirabayashi H., Takakura Y., Hashida M. Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharm. Res. 12:1995;209-214.
83. Nishikawa M., Kamijyo A., Fujita T., Takakura Y., Sezaki H., Hashida M. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm. Res. 10:1993;1253-1261.
84. Fujita T., Nishikawa M., Ohtsubo Y.et al. Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J. Drug Target. 2:1994;157-165.
85. Nishikawa M., Miyazaki C., Yamashita F., Takakura Y., Hashida M. Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. Am. J. Physiol. 268:1995;G849-G856.
86. Hirabayashi H., Nishikawa M., Takakura Y., Hashida M. Development and pharmacokinetics of galactosylated poly(L-glutamic) acid as a biodegradable carrier for liver-specific drug delivery. Pharm. Res. 13:1995;880-884.
87. Fiume L., Busi C., Stefano G., Mattioli A. Targeting of antiviral drugs to the liver using glycoprotein carriers. Adv. Drug Deliv. Rev. 14:1994;51-65.
88. Jansen R.W., Molema G., Ching T.L.et al. Hepatic endocytosis of various types of mannose-terminated albumins: What is important, sugar recognition, net charge of the combination of these features. J. Biol. Chem. 266:1991;3343-3348.
89. Miyao T., Takakura Y., Akiyama T., Yoneda F., Sezaki H., Hashida M. Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev. 5:1995;115-121.
90. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45:1994;932-943.
91. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12:1995;825-830.
92. Crooke S.T. Delivery of oligonucleotides and polynucleotides. J. Drug Target. 3:1995;185-190.
93. Mahato R.I., Takakura Y., Hashida M. Nonviral vectors for in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;133-172.
94. Wu G.Y., Wu C.H. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263:1988;14621-14624.
95. Findeis M.A., Wu C.H., Wu G.Y. Ligand-based carrier systems for delivery of DNA to hepatocytes. Methods Enzymol. 247:1994;341-351.
96. E.P. Carmichael, H.C. Chiou, M.A. Findeis, G.L. Spitalny, J.R. Merwin, Targeted delivery of anti-hepatitis B antisense oligonucleotides, in: S. Akhtar (Ed.), Delivery Strategies for Antisense Oligonucleotide Therapies, CRC Press, Boca Raton, FL, 1995, pp. 267-282.
97. Lu K.-M., Fischman A.J., Jyawook S.L., Hendricks K., Tompkins R.G., Yarmush M.L. Antisense DNA delivery in vivo: Liver targeting by receptor-mediated uptake. J. Nucl. Med. 35:1994;269-275.
98. Perales J.C., Ferkol T., Beegen H., Ratnoff O.D. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA. 91:1994;4086-4090.
99. R.I. Mahato, S. Takemura, M. Nishikawa, Y. Takakura, M. Hashida, Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine) in mice, 53 (1997) 887-895.
100. Takemura S., Nishikawa M., Takakura Y., Hashida M. Pharmacokinetic analysis of hepatocyte-specific targeting of plasmid DNA using galactosylated poly-L-lysine. Proc. Int. Symp. Control. Rel. Bioact. Mater. 23:1996;901-902.